EX-12.1 5 ex12_109302011.htm PROGENICS EXHIBIT 12.1 09/30/2011 ex12_109302011.htm

Exhibit 12.1
 
Progenics Pharmaceuticals, Inc.
Ratio of Earnings (Loss) to Combined Fixed Charges and Preferred Stock Dividends
(in thousands)
 
   
Nine Months
Ended
September 30,
  
Years Ended December 31,
  
   
2011
  
2010
  
2009
  
2008
  
2007
  
2006
  
Determination of earnings (loss):
                          
Income (loss) from operations(1)
  
$
21,127
  
$
(69,820
)
$
(30,612
)
$
(44,672
)
$
(43,688
)
$
(21,497
)
Add:
                          
Fixed charges
  
492
  
709
  
555
  
594
  
483
  
339
  
                           
Earnings (loss), as adjusted
  
$
21,619
  
$
(69,111
)
$
(30,057
)
$
(44,078
)
$
(43,205
)
$
(21,158
)
                           
Fixed charges:
                          
                           
Estimate of interest within rental expense
  
492
  
709
  
555
  
594
  
483
  
339
  
                           
Fixed charges
  
$
492
  
$
709
  
$
555
  
$
594
  
$
483
  
$
339
  
                           
Preferred stock dividends
  
$
-
  
$
-
  
$
-
  
$
-
  
$
-
  
$
-
  
                           
                                       
Ratio of earnings (loss) to fixed charges and preferred stock dividends
  
44
  
*
  
*
  
*
  
*
  
*
  
Coverage deficiency amount for total fixed charges and preferred stock dividends (2)
    
-
  
$
69,820
  
$
30,612
  
$
44,672
  
$
43,688
  
$
21,497
  
_____________________
(1)           Excludes loss in joint venture of $121 in 2006.
(2)
For the full years presented, the Company’s coverage ratio is less than one-to-one and it must generate additional earnings of these specified amounts to achieve a coverage ratio of 1:1.